ReviewAsian Pacific journal of cancer prevention : APJCP2026
Prognostic Stratification of Highly Differentiated Thyroid Cancer Based on Molecular Genetic Studies.
Review in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this literature review was to identify the critical role of molecular-genetic and epigenetic factors in predicting the course of differentiated thyroid carcinoma (DTC), to improve diagnostic and therapeutic strategies for this disease.
methodsAnalytical and comparative review methods of publications available in the databases of Scopus, Web of Science, and PubMed were employed.
resultsThe results demonstrated that the presence of specific mutations and epigenetic modifications significantly influenced the likelihood of recurrence, metastatic potential, and tumour sensitivity to conservative treatment, including radioactive iodine therapy. Mutations in the B-Raf kinase family protein, telomerase reverse transcriptase, rat sarcoma genes, and rearranged during transfection/papillary thyroid carcinoma rearrangements were shown to be associated with an increased risk of recurrence, metastatic activity, and reduced efficacy of radioiodine treatment. Epigenetic markers such as promoter methylation of tumour suppressor genes, global hypomethylation, and microRNAs (miR-146b, miR-221, miR-375) emerged as promising predictors of aggressive disease progression. The review outcomes indicate that a personalized approach based on identifying the molecular profile of the tumour allows for more accurate risk assessment of adverse outcomes and determination of prospects for targeted therapy.
conclusionThe practical significance of this work lies in the possibility of considering the identified genomic and epigenomic features when choosing surgical intervention and adjuvant therapy, thereby increasing the chances for long-term remission. Additionally, it emphasizes the standardization of analytical methods and the development of a unified system for evaluating the combined genetic alterations, which could enhance the quality of prognostic stratification and more effectively tailor treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.